P003: Immunotherapy for Hematologic Malignancies

P003 is a highly targeted biosimilar developed for the treatment of specific blood cancers and autoimmune conditions. It works by depleting certain immune cells, offering a powerful option for patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma. P003 is designed to provide a cost-effective alternative without compromising efficacy, bringing advanced therapeutic solutions to more patients worldwide.